SEARCH

SEARCH BY CITATION

References

  • 1
    Fuster V, Rydén LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 211850.
  • 2
    Rossi A, Enriquez-Sarano M, Burnett Jr JC, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000; 35: 125662.
  • 3
    Lellouche N, Berthier R, Mekontso-Dessap A et al. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol 2005; 95: 13802.
  • 4
    Yamada T, Murakami Y, Okada T et al. Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation. Am J Cardiol 2006; 97: 17414.
  • 5
    Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 16428.
  • 6
    Loricchio ML, Cianfrocca C, Pasceri V et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007; 99: 14214.
  • 7
    Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009; 131: 2349.
  • 8
    Vasan RS, Larson MG, Levy D et al. Doppler transmitral flow indexes and risk of atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2003; 91: 107983.
  • 9
    Kurl S, Ala-Kopsala M, Ruskoaho H et al. Plasma N-terminal fragments of natriuretic peptides predict the risk of stroke and atrial fibrillation in men. Heart 2009; 95: 106771.
  • 10
    Badran HM, Eid MA, Michael A. Doppler-derived indexes and B-type natriuretic peptide in prediction of paroxysmal atrial fibrillation in essential hypertension: a prospective study. Echocardiography 2007; 24: 91122.
  • 11
    Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 54857.
  • 12
    Wazni OM, Martin DO, Marrouche NF et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110: 1247.
  • 13
    GISSI-AF Investigators, Disertori M, Latini R et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 160617.
  • 14
    Duru F, Barton M, Lüscher TF, Candinas R. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res 2001; 49: 27280.
  • 15
    Nakazawa Y, Ashihara T, Tsutamoto T, Ito M, Horie M. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm 2009; 6: 72530.
  • 16
    Gegenhuber A, Struck J, Dieplinger B et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007; 13: 429.
  • 17
    Stoiser B, Mörtl D, Hülsmann M et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 7718.
  • 18
    Disertori M, Latini R, Maggioni AP et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown) 2006; 7: 2938.
  • 19
    Masson S, Latini R, Anand IS et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 152838.
  • 20
    Latini R, Masson S, Anand IS et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 12429.
  • 21
    Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 25461.
  • 22
    Pencina MJ, DAgostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23: 210923.
  • 23
    Benjamin EJ, Chen PS, Bild DE et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009; 119: 60618.
  • 24
    Raitt MH, Volgman AS, Zoble RG et al. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2006; 151: 3906.
  • 25
    Fung JW, Yu CM, Yip G et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92: 40610.
  • 26
    McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 105664.
  • 27
    Möllmann H, Weber M, Elsässer A et al. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 2008; 72: 9215.
  • 28
    Sacher F, Corcuff JB, Schraub P et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J 2008; 29: 12905.
  • 29
    Yoshihara F, Nishikimi T, Sasako Y et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol 2002; 39: 28894.
  • 30
    Disertori M, Lombardi F, Barlera S et al. Clinical predictors of atrial fibrillation recurrence in the GISSI-AF trial. Am Heart J, 2010; 159: 85763.